Literature DB >> 19033822

Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta.

Claudia Wagner1, Ingrid Kloeting, Ruth H Strasser, Christof Weinbrenner.   

Abstract

BACKGROUND AND
OBJECTIVE: Postconditioning by repetitive I/R cycles immediately after onset of reperfusion protects the heart. Metabolic disorders undermine the protection of preconditioning. The present study tested whether postconditioning protects hearts from rats with established metabolic syndrome [Wistar-Ottawa-Karlsburg W rats (WOKW)]. METHODS AND
RESULTS: After 28 weeks of age, WOKW rats were much heavier than DA (Dark Agouti) and Wistar control rats and showed the pattern of the metabolic syndrome. Postconditioning was performed by 3 30-second cycles of reperfusion/ischemia immediately after the regional ischemia (30 minutes). Infarct size was comparable in all control hearts from DA, Wistar, and WOKW rats (58 +/- 2%, 49 +/- 3%; 49 +/- 2%, respectively). Postconditioning significantly reduced the infarct size in DA rats (39 +/- 5%) and Wistar rats (29 +/- 3%). In WOKW rats, the infarct sparing effect of postconditioning was lost (43 +/- 4%).GSK-3beta and Erk are involved in the signaling of postconditioning. Therefore, the phosphorylation of these proteins was determined by Western blot analysis. Postconditioning significantly increased the phosphorylation of GSK-3beta in DA and Wistar rats (1.6-fold in DA rats, 2.3-fold in Wistar rats, P < 0.05) but failed to do so in WOKW rats. Similarly, a trend for an increased phosphorylation of Erk was found in DA rats but not in WOKW rats. Thus the inefficacy of postconditioning in reducing infarct size in rats with metabolic syndrome is paralleled by a lack of phosphorylation of GSK-3beta and Erk.
CONCLUSION: The metabolic syndrome, as shown in this animal model, completely abrogates the postconditioning. This blockade involves the phosphorylation of GSK-3beta. Further studies have to evaluate whether this block of postconditioning makes patients with a metabolic syndrome more susceptible to myocardial damage after infarction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033822     DOI: 10.1097/FJC.0b013e31818c12a7

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  25 in total

Review 1.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

Review 2.  Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus.

Authors:  Reza Badalzadeh; Behnaz Mokhtari; Raana Yavari
Journal:  J Physiol Sci       Date:  2015-03-01       Impact factor: 2.781

Review 3.  Ischaemic conditioning: pitfalls on the path to clinical translation.

Authors:  Karin Przyklenk
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

Review 4.  Autophagy, myocardial protection, and the metabolic syndrome.

Authors:  Zoltan Giricz; Robert M Mentzer; Roberta A Gottlieb
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

5.  Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

Authors:  Karin Przyklenk; Michelle Maynard; Dale L Greiner; Peter Whittaker
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

6.  Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.

Authors:  Joseph Wider; Vishnu V R Undyala; Peter Whittaker; James Woods; Xuequn Chen; Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2018-03-09       Impact factor: 17.165

Review 7.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

Review 8.  Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum.

Authors:  Karin Przyklenk
Journal:  Drugs Aging       Date:  2011-05-01       Impact factor: 3.923

9.  Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3beta, and apoptosis.

Authors:  Claudia Wagner; Diana Tillack; Gregor Simonis; Ruth H Strasser; Christof Weinbrenner
Journal:  Mol Cell Biochem       Date:  2010-01-07       Impact factor: 3.396

Review 10.  Protective ischaemia in patients: preconditioning and postconditioning.

Authors:  Asger Granfeldt; David J Lefer; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2009-04-27       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.